News
AstraZeneca to initiate a new study of BRILINTA in patients with PAD
AstraZeneca announced plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease (PAD), a condition affecting approximately 27 million people in Europe and North America. PAD patients are...
News
GSK to acquire Human Genome Sciences for US$14.25 per share in cash
GlaxoSmithKline plc and Human Genome Sciences have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. The transaction values HGS at approximately US$3.6 billion on an equity...
News
GSK and Theravance announce regulatory submissions for FF/VI
GlaxoSmithKline plc (GSK) and Theravance, Inc. announced the submission of regulatory applications in the US and European Union for the once-daily investigational medicine fluticasone furoate "FF"/vilanterol "VI" (FF/VI) for patients with chronic obstructive pulmonary disease (COPD) and a...
News
Boehringer Ingelheim pursuing health care innovationBoehringer Ingelheim pursuing health care innovation
In future patients with certain diseases, especially chronic ones, should be treated in a more holistic approach beyond drug treatment only. Thus Boehringer Ingelheim is concentrating on new business models and healthcare innovation and...
News
Abbott Introduces OneLab, a Novel Integrated Web-Based Software Platform to Manage the Vast Amounts of Information Flowing Through the Lab
As health care systems around the world face challenges such as labor shortages, increased regulation and budget constraints, they rely on technology to help manage the impact. To assist in addressing these challenges, Abbott announced...
News
Drug fails to curb heart bypass complications, but surgery gets safer
A drug designed to shield the heart from injury during bypass surgery failed to reduce deaths, strokes and other serious events among patients at high risk of complications, according to a large, prospective study lead by researchers at...
News
Boehringer Ingelheim establishes translational research collaboration with Harvard University
Boehringer Ingelheim has established a translational research collaboration with the Presidents and Fellows of Harvard College. The goal of the collaboration is for the scientists of Boehringer Ingelheim to work together with the scientific...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read